Robert Coleman, MD

Latest in Lung, Genitourinary, Gynecologic, and Breast Cancers From ASCO 2022: Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin Kalinsky

June 7th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Practical Advice on Sequencing Therapies and the Care of Cervical Cancer Patients

November 30th 2021

Closing out his discussion on the treatment of cervical cancer, Robert L. Coleman, MD, FACOG, FACS, provides thoughts on the optimal sequencing of therapy and importance of clinical trials.

Advanced Cervical Cancer: Toxicity Management With Balstilimab + Zalifrelimab

November 30th 2021

Robert L. Coleman, MD, FACOG, FACS, shares practical advice on managing toxicities while treating cervical cancer with the combination of balstilimab and zalifrelimab.

Combining Balstilimab With Zalifrelimab in Patients With Advanced Cervical Cancer

November 30th 2021

Expert insight on the combination of balstilimab, a PD-1 inhibitor, and zalifrelimab, a CTLA-4 inhibitor, in patients with recurrent or metastatic cervical cancer.

Balstilimab in Advanced Cervical Cancer: Rationale and Key Efficacy Outcomes

November 30th 2021

Focusing on novel immune checkpoint inhibitors, Robert L. Coleman, MD, FACOG, FACS, breaks down preclinical and clinical data that support use of balstilimab in patients with advanced cervical cancer.

An Overview of the Cervical Cancer Landscape: Key Advances and Recent Approvals

November 30th 2021

Robert L. Coleman, MD, FACOG, FACS, reviews the treatment landscape of cervical cancer and identifies recent approvals that have improved patient care.

Dr. Coleman on the Utility of Biomarkers for Precision Medicine in Ovarian Cancer

June 16th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the utility of biomarkers in precision medicine.

Dr. Coleman on the Future of PARP Inhibitors in Ovarian Cancer

September 29th 2018

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the future of PARP inhibitors in patients with ovarian cancer.

Dr. Coleman on Classifying Patients With Ovarian Cancer

August 31st 2018

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the classification of patients with ovarian cancer.

Dr. Coleman on Immunotherapy in Ovarian Cancer

August 23rd 2018

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in ovarian cancer.

Dr. Coleman on the Role of Ramucirumab in Gynecologic Cancer

January 30th 2018

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of ramucirumab (Cyramza) in patients with gynecologic cancer.

Dr. Robert Coleman on BRCA Testing in Ovarian Cancer

August 27th 2016

Dr. Robert Coleman on the Importance of BRCA Testing in Ovarian Cancer

August 4th 2016

Robert Coleman, MD a professor in the Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses the importance of BRCA testing for patients diagnosed with ovarian cancer.